Skip to main content

Table 2 Study findings summary

From: Efficacy of liraglutide in patients with diabetic nephropathy: a meta-analysis of randomized controlled trials

Outcome Number of studies Sample Heterogeneity Analysis model Statistical method WMD/SMD (95% CI) P-value
Test/Control χ2 I2 P
FBG 14 624/625 141.13 91% < 0.00001 Random-effects Inverse Variance −0.66[− 1.04,-0.27] 0.0009
PBG 8 370/370 12.94 46% 0.07 Fixed-effects Inverse Variance −1.51[− 1.68,-1.34] < 0.00001
HbA1c 14 515/523 217.29 94% < 0.00001 Random-effects Inverse Variance −0.61[− 0.95,-0.27] 0.0004
BMI 10 378/386 98.99 91% < 0.00001 Random-effects Inverse Variance −2.27[−2.98,-1.56] < 0.00001
eGFR 3 94/95 15.20 87% 0.0005 Random-effects Inverse Variance 6.46[−3.69,16.61] 0.21
UACR 10 391/397 366.83 98% < 0.00001 Random-effects Inverse Variance −2.34[−3.65,-1.03] 0.0005
BUN 4 204/204 48.46 94% < 0.00001 Random-effects Inverse Variance −1.06[−2.22,0.10] 0.07
Scr 11 531/532 94.16 89% < 0.00001 Random-effects Inverse Variance −0.81[−1.22,-0.4] < 0.0001
CysC 2 32/39 0.44 0% 0.5 Fixed-effects Inverse Variance −0.7[−1.01,-0.39] < 0.0001
IL-6 5 248/248 130.43 97% < 0.00001 Random-effects Inverse Variance −2.03[−3.30,-0.77] 0.002
TNF-α 6 303/303 38.24 87% < 0.00001 Random-effects Inverse Variance −1.16[−1.66,-0.66] < 0.00001